Accelevir Diagnostics LLC

Baltimore, MD Part of AGI Scientific, LLC

UEI
F6SKM7YHCUS7
CAGE
7FL22
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
Corporate family
SAM.gov registration date
Physical address
701 E Pratt St #4016, Baltimore, MD 21202, USA
Website
accelevirdx.com
Founded
2015
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 $0
FY2023 $2,000,000

Contract awards

Award Agency Obligated Awarded
Proviral sequencing driven development of enhanced IPDAV2 with global HIV-1 group m coverage to support worldwide… 75N93023C00017 National Institute of Allergy and Infectious Diseases (NIH) $2,000,000
The objective of this contract is to adapt the ipda for the measurement of latent HIV-1 for individuals with HIV-1… 75N93020C00015 National Institute of Allergy and Infectious Diseases (NIH) $299,975
Custom DNA assay analysis 75N93019P00576 National Institute of Allergy and Infectious Diseases (NIH) $13,500

Grant awards

Award Agency Obligated Awarded
HIV-1 envlrs: a scalable, sequence-based assay for in-depth assessment of HIV-1 bnab resistance R43AI165126 National Institute of Allergy and Infectious Diseases (NIH) $900,000
Ipda for high-priority HIV-1 subtype c to enable global eradication trials R43AI165128 National Institute of Allergy and Infectious Diseases (NIH) $1,500,000
Centralized resource to accurately quantify latent and expressed hivreservoirs R24AI143502 National Institute of Allergy and Infectious Diseases (NIH) $1,520,199
Centralized resource to accurately quantify latent and expressed HIV reservoirs U24AI143502 National Institute of Allergy and Infectious Diseases (NIH) $11,349,721
Development of intact proviral DNA assays for SIV and shiv R43AI149816 National Institute of Allergy and Infectious Diseases (NIH) $300,000

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Vitruvian Bio, LLC UEI JHJJANE1ALC6 Baltimore, MD 541713 Research and Development in Nanotechnology
Marpam Pharma LLC UEI FJN8ZEF912K7 Oakdale, MN 541714 Research and Development in Biotechnology (except Nanobiotechnology)
JBI UEI DKDUTDKCJQE6 Ithaca, NY 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Imquest Biosciences, Inc. UEI Y7ETNZCNSLM5 Frederick, MD 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Lo Biosciences, Inc. UEI JPVWZEYKLXN3 North Bethesda, MD 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Accelevir Diagnostics LLC is a woman-owned small business that provides research and development services related to HIV diagnostics and measurement of the HIV latent reservoir. The company has developed proprietary technology for HIV testing and measurement, including the intact proviral DNA assay (IPDA) for quantification of intact and defective HIV proviruses.

Through prime contract awards, Accelevir Diagnostics has provided research and development of enhanced diagnostics to support global HIV cure and clinical trials, including adapting the IPDA to enable measurement of latent HIV-1 for individuals with subtype CRF-1_AE. These contracts were awarded by the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, with total potential values up to $2 million. The contracts were set aside for total small businesses. Accelevir Diagnostics has also provided custom DNA assay analysis for the National Institute of Allergy and Infectious Diseases through a $13,500 purchase order contract.

Through prime grant awards, Accelevir Diagnostics has received funding to develop the HIV-1 ENVLRS assay to assess HIV-1 broadly neutralizing antibody resistance and predict efficacy. Additional grants have supported expanding the IPDA to cover HIV-1 subtype C to enable global eradication trials, as well as resources to quantify latent and expressed HIV reservoirs. These awards have been provided by the National Institute of Allergy and Infectious Diseases, with total potential funding over $10 million.

Quick answers

Is Accelevir Diagnostics LLC registered in SAM.gov?

Yes. Accelevir Diagnostics LLC's SAM.gov registration is active through February 10, 2027.

How much has Accelevir Diagnostics LLC received in federal contracts?

Federal contracts obligated $2,000,000 to Accelevir Diagnostics LLC in fiscal years 2023 through 2027.

What is Accelevir Diagnostics LLC's most recent federal award?

Accelevir Diagnostics LLC's most recent federal contract award is Proviral sequencing driven development of enhanced IPDAV2 with global HIV-1 group m coverage to support worldwide… (75N93023C00017), from National Institute of Allergy and Infectious Diseases (NIH), on June 1, 2023.

On GovTribe

See Accelevir Diagnostics LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login